Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic ER+ Her2- Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06176261
What this trial is testing

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Who this might be right for
Breast CancerBreast Cancer FemaleMetastatic Triple-Negative Breast Carcinoma+4 more
Nancy Lin, MD 58
Testing effectiveness (Phase 2)Looking for participantsNCT04585750
What this trial is testing

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Who this might be right for
Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more
PMV Pharmaceuticals, Inc 300
Testing effectiveness (Phase 2)UnknownNCT02910050
What this trial is testing

Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Xu fei 58
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07173556
What this trial is testing

A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Qilu Pharmaceutical Co., Ltd. 96
Early research (Phase 1)Study completedNCT02900664
What this trial is testing

PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Who this might be right for
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Novartis Pharmaceuticals 283
Testing effectiveness (Phase 2)Ended earlyNCT02374099
What this trial is testing

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Who this might be right for
Breast Neoplasms
Celgene 97
Testing effectiveness (Phase 2)Active Not RecruitingNCT06105632
What this trial is testing

Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Who this might be right for
Advanced or Metastatic Breast Cancer
Pfizer 333
Testing effectiveness (Phase 2)Study completedNCT00540358
What this trial is testing

Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Sanofi 123
Large-scale testing (Phase 3)Ended earlyNCT01548534
What this trial is testing

A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerProgesterone Receptor Positive TumorEstrogen Receptor Positive Tumor+1 more
University Hospital, Tours 65
Early research (Phase 1)Active Not RecruitingNCT05463952
What this trial is testing

Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)

Who this might be right for
Breast Neoplasms
Pfizer 6
Testing effectiveness (Phase 2)Looking for participantsNCT06062498
What this trial is testing

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Who this might be right for
Estrogen-receptor-positive Breast CancerHER2/Neu-Negative Breast CancerAdvanced Breast Cancerv+1 more
Northwestern University 174
Early research (Phase 1)Study completedNCT03554044
What this trial is testing

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+11 more
University of California, San Francisco 20
Testing effectiveness (Phase 2)Study completedNCT05889728
What this trial is testing

Pilot Trial to Assess 68Ga Bombesin PET/CT (NeoB) Imaging for Staging of Breast Cancer

Who this might be right for
Breast Cancer
St Vincent's Hospital, Sydney 20
Large-scale testing (Phase 3)Study completedNCT00785291
What this trial is testing

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+6 more
National Cancer Institute (NCI) 799
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Testing effectiveness (Phase 2)Study completedNCT02536742
What this trial is testing

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
ETOP IBCSG Partners Foundation 124
Large-scale testing (Phase 3)Active Not RecruitingNCT05296798
What this trial is testing

Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 922
Early research (Phase 1)Active Not RecruitingNCT04993430
What this trial is testing

HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

Who this might be right for
ER-Positive, HER2-Negative Breast Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd. 46
Testing effectiveness (Phase 2)Study completedNCT00951054
What this trial is testing

NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Nippon Kayaku Co., Ltd. 61
Testing effectiveness (Phase 2)Looking for participantsNCT06110793
What this trial is testing

Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center 56
Next Page